AURORA CANNABIS INC (ACB.CA) Fundamental Analysis & Valuation
TSX:ACB • CA05156X8504
Current stock price
4.67 CAD
-0.12 (-2.51%)
Last:
This ACB.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ACB.CA Profitability Analysis
1.1 Basic Checks
- In the past year ACB has reported negative net income.
- In the past year ACB has reported a negative cash flow from operations.
- In the past 5 years ACB reported 4 times negative net income.
- In the past 5 years ACB reported 4 times negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -11.45%, ACB is in line with its industry, outperforming 48.39% of the companies in the same industry.
- ACB has a Return On Equity (-16.55%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.45% | ||
| ROE | -16.55% | ||
| ROIC | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ACB's Gross Margin of 1.35% is on the low side compared to the rest of the industry. ACB is outperformed by 83.87% of its industry peers.
- ACB's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
2. ACB.CA Health Analysis
2.1 Basic Checks
- ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ACB has been increased compared to 1 year ago.
- Compared to 5 years ago, ACB has less shares outstanding
- ACB has a better debt/assets ratio than last year.
2.2 Solvency
- ACB has an Altman-Z score of -10.46. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
- ACB's Altman-Z score of -10.46 is on the low side compared to the rest of the industry. ACB is outperformed by 83.87% of its industry peers.
- ACB has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.06, ACB is doing good in the industry, outperforming 70.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.46 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
- ACB has a Current Ratio of 3.06. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
- ACB has a better Current ratio (3.06) than 77.42% of its industry peers.
- ACB has a Quick Ratio of 1.48. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
- ACB has a Quick ratio of 1.48. This is in the better half of the industry: ACB outperforms 67.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.06 | ||
| Quick Ratio | 1.48 |
3. ACB.CA Growth Analysis
3.1 Past
- The earnings per share for ACB have decreased strongly by -502.65% in the last year.
- Looking at the last year, ACB shows a quite strong growth in Revenue. The Revenue has grown by 16.54% in the last year.
- The Revenue has been growing slightly by 6.94% on average over the past years.
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
3.2 Future
- ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.
- The Revenue is expected to grow by 1.94% on average over the next years.
EPS Next Y-2493.7%
EPS Next 2Y27.12%
EPS Next 3Y76.74%
EPS Next 5Y103.58%
Revenue Next Year5.63%
Revenue Next 2Y-0.69%
Revenue Next 3Y5.96%
Revenue Next 5Y1.94%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. ACB.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
- Based on the Price/Forward Earnings ratio of 57.80, the valuation of ACB can be described as expensive.
- The rest of the industry has a similar Price/Forward Earnings ratio as ACB.
- The average S&P500 Price/Forward Earnings ratio is at 21.68. ACB is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 57.8 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ACB's earnings are expected to grow with 76.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y76.74%
5. ACB.CA Dividend Analysis
5.1 Amount
- ACB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ACB.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:ACB (4/28/2026, 7:00:00 PM)
4.67
-0.12 (-2.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength39.37
Industry Growth47.76
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)06-16 2026-06-16/amc
Inst Owners13.03%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap264.84M
Revenue(TTM)373.12M
Net Income(TTM)-88.74M
Analysts74
Price Target7.77 (66.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-336.98%
Min EPS beat(2)-587.94%
Max EPS beat(2)-86.02%
EPS beat(4)0
Avg EPS beat(4)-329.23%
Min EPS beat(4)-587.94%
Max EPS beat(4)-86.02%
EPS beat(8)2
Avg EPS beat(8)402.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.46%
Revenue beat(4)3
Avg Revenue beat(4)0.88%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)2.46%
Revenue beat(8)6
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)4.15%
Revenue beat(16)9
Avg Revenue beat(16)1.91%
PT rev (1m)8.47%
PT rev (3m)-2.31%
EPS NQ rev (1m)-70%
EPS NQ rev (3m)-355.03%
EPS NY rev (1m)-2.38%
EPS NY rev (3m)-62.33%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-20.65%
Revenue NY rev (1m)-0.54%
Revenue NY rev (3m)-4.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 57.8 | ||
| P/S | 0.71 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.49 | ||
| P/tB | 0.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.91
EYN/A
EPS(NY)0.08
Fwd EY1.73%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS6.58
BVpS9.46
TBVpS8.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.45% | ||
| ROE | -16.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.35% | ||
| FCFM | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score3
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 87.54% | ||
| Cap/Sales | 5.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.06 | ||
| Quick Ratio | 1.48 | ||
| Altman-Z | -10.46 |
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
EPS Next Y-2493.7%
EPS Next 2Y27.12%
EPS Next 3Y76.74%
EPS Next 5Y103.58%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
Revenue Next Year5.63%
Revenue Next 2Y-0.69%
Revenue Next 3Y5.96%
Revenue Next 5Y1.94%
EBIT growth 1Y-17.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.2%
EBIT Next 3Y33.11%
EBIT Next 5Y21.95%
FCF growth 1Y63.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.56%
OCF growth 3YN/A
OCF growth 5YN/A
AURORA CANNABIS INC / ACB.CA Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?
ChartMill assigns a fundamental rating of 2 / 10 to ACB.CA.
What is the valuation status of AURORA CANNABIS INC (ACB.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to AURORA CANNABIS INC (ACB.CA). This can be considered as Overvalued.
How profitable is AURORA CANNABIS INC (ACB.CA) stock?
AURORA CANNABIS INC (ACB.CA) has a profitability rating of 1 / 10.
Can you provide the financial health for ACB stock?
The financial health rating of AURORA CANNABIS INC (ACB.CA) is 4 / 10.